Govt issues alert on Nimesulide

On April 2024, the Indian Pharmacopoeia Commission (IPC) issued a drug safety alert regarding Nimesulide, an anti-inflammatory drug, citing potential skin rashes as an adverse effect.

Key Points

Nimesulide Overview: Nimesulide, classified as a Non-steroidal anti-inflammatory drug (NSAID), is prescribed to alleviate pain, inflammation, and swelling associated with various conditions, including fever, menstrual cramps, and osteoarthritis.
Identifying Allergic Reactions: Patients with known drug allergies or underlying health issues, such as kidney or liver disease, should inform their doctors.
Administration Guidelines: Patients are advised to follow prescribed dosages, take the medication with food, and discontinue its use as per the doctor's instructions.
Contraindications: Individuals with blood coagulation issues, children, pregnant or nursing women, and those with a history of stomach ulcers, heart failure, or liver and kidney conditions should avoid Nimesulide.
Monitoring and Response: Patients should remain vigilant for any adverse reactions, particularly within the initial days of usage.
Historical Context: Nimesulide faced bans in several countries, including Switzerland, Spain, and the US, due to safety concerns.
In India, its usage for adults persists but is not recommended for children since 2011.